The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders

CONTACT US HERE:

https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=156029&from=4

CLASS PERIOD: May 9, 2024 to May 8, 2025

ALLEGATIONS: According to the complaint, throughout the class period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers. On July 25, 2024, Iovance announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on 1) "the iCTC completed annual scheduled maintenance in December" and "capacity was reduced by more than half for about 1 month," 2) "[l]ower Proleukin sales" than the company expected, and 3) "the variable pace at which ATCs began treatment patients." Following this news, the price of Iovance's common stock declined dramatically. From a closing market price of $3.17 per share on May 8, 2025, Iovance's stock price fell to $1.75 per share on May 9, 2025, a decline of about 44.795% in the span of just a single day.

DEADLINE: July 14, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=156029&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of IOVA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 14, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-announces-the-filing-of-a-securities-class-action-on-behalf-of-iovance-biotherapeutics-inciova-shareholders-302501369.html

SOURCE The Gross Law Firm